ACCESS Newswire
17 Aug 2022, 11:07 GMT+10
Experienced Leader in Market Access to Bolster Relief's U.S. Commercial Operations
GENEVA, SWITZERLAND / ACCESSWIRE / August 17, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (' Relief '), a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced today the appointment of David McCullough as Senior Director and Head of U.S. Market Access, effective August 22 nd . In this newly created position, reporting to Anthony Kim, Senior Vice President and Head of U.S. Commercial Operations, Mr. McCullough will direct Relief's market access strategy and operations to ensure timely and effective access to Relief's products for patients in the U.S.
'David's appointment as Head of U.S. Market Access signifies an important milestone for Relief, as we have now completed the hiring of the U.S. Commercial Team and are one step closer to providing patient access to treatments for diseases with high unmet medical needs,' stated Mr. Kim. 'As we continue to grow, David's more than 20 years of extensive commercial experience working with payors, physicians and specialty pharmacies to help ensure access for patients and their families, will be invaluable. With expertise and relationships forged during his tenures at Mirum Pharmaceuticals, Inc., Novartis Gene Therapies, Spark Therapeutics and other companies, we look forward to leveraging his broad knowledge of market access in preparation for our October 2022 U.S. launch of PKU GOLIKE ® . With continued commercialization of Relief products on the horizon, David serves as a welcome addition to our commercial leadership team.'
'Relief's mission to develop a robust therapeutic portfolio for rare and ultra-rare diseases synergistically aligns with my desire to increase patient access to rare disease treatment options,' added Mr. McCullough. 'I look forward to contributing to the commercial sales of PKU GOLIKE ® and additional products in Relief's pipeline.'
Prior to joining Relief, Mr. McCullough served as National Account Director (Payer Account Lead) at Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of rare diseases, where he was responsible for building out the company's Medicaid launch strategy and supporting the expansion of key market access policies. Previously, he held several positions of increasing responsibility at Novartis Gene Therapies (formerly AveXis), most recently, as Director National Accounts, where he was responsible for successfully negotiating multiple Value-Based Agreements and 10 state Medicaid policies. Before that, he worked as a Patient Access Liaison at Spark Therapeutics, supporting the launch of a first-of-its-kind gene therapy in the inherited retinal disease space and also aided in the build-out of patient services and market access operations. Before Spark Therapeutics, Mr. McCullough was Associate Director, Patient Services Southeast at Shire. Earlier in his career, Mr. McCullough held numerous market access and commercial operations positions at various biotechnology and pharmaceutical companies, including an Institutional Specialty Manager at MedImmune and a Territory Manager at Abbott Laboratories.
Mr. McCullough earned a BA in Speech/Public Relations from McNeese State University, a BS in Ministry and Theology from St. Louis Christian College, and served four years in the United States Coast Guard.
About RELIEF THERAPEUTICS Holding SA
Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of metabolic, dermatological and pulmonary rare diseases with a portfolio of clinical and marketed assets that serve unmet patient needs. Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including UCDs and Maple Syrup Urine Disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Relief's 2021 acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH brought to Relief a diverse pipeline of marketed and development-stage programs.
RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com and follow Relief on LinkedIn .
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Financial Officer and Treasurer
[email protected]
FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including those risks discussed in RELIEF THERAPEUTICS Holding SA's filings with the SIX and the U.S. Securities and Exchange Commission, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holdings AG
Get a daily dose of Atlanta Leader news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Atlanta Leader.
More InformationEVERGLADES, Florida: Over the weekend, a diverse coalition of environmental activists, Native American leaders, and residents gathered...
BEIJING, China: China's national soccer team may struggle to stir excitement, but its humanoid robots are drawing cheers — and not...
]LONDON, U.K.: A World Health Organization (WHO) expert group investigating the origins of the COVID-19 pandemic released its final...
DOVER, Delaware: California Governor Gavin Newsom has taken legal aim at Fox News, accusing the network of deliberately distorting...
FRANKFURT, Germany: Germany has become the latest country to challenge Chinese AI firm DeepSeek over its data practices, as pressure...
TORONTO, Canada: Harvard University and the University of Toronto have created a backup plan to ensure Harvard graduate students continue...
NEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
Vancouver, Canada: A high-stakes legal showdown is brewing in the world of athleisure. Lululemon, the Canadian brand known for its...
LONDON, U.K.: British oil giant Shell has denied reports that it is in talks to acquire rival oil company BP. The Wall Street Journal...
NEW YORK, New York - U.S. stock markets closed firmly in positive territory to start the week Monday, with the S&P 500 and Dow Jones...
WASHINGTON, D.C.: On Friday, President Donald Trump announced that he was halting trade discussions with Canada due to its decision...